Nanobiotix Future Growth

Future criteria checks 1/6

Nanobiotix is forecast to grow earnings and revenue by 16.2% and 7.7% per annum respectively while EPS is expected to grow by 22.9% per annum.

Key information

16.2%

Earnings growth rate

22.9%

EPS growth rate

Biotechs earnings growth	42.4%
Revenue growth rate	7.7%
Future return on equity	n/a
Analyst coverage	Good
Last updated	12 Nov 2024

Recent future growth updates

No updates

Recent updates

Earnings and Revenue Growth Forecasts

DB:5NRA - Analysts future estimates and past financials data (EUR Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	47	-19	51	-5	4
12/31/2025	32	-44	-43	-47	5
12/31/2024	17	-51	-49	-41	5
6/30/2024	42	-33	-2	-1	N/A
3/31/2024	39	-37	-7	-7	N/A
12/31/2023	36	-40	-13	-12	N/A
9/30/2023	21	-49	-25	-25	N/A
6/30/2023	7	-59	-37	-37	N/A
3/31/2023	6	-58	-37	-37	N/A
12/31/2022	5	-57	-37	-37	N/A
9/30/2022	4	-50	-35	-35	N/A
6/30/2022	3	-43	-33	-32	N/A
3/31/2022	3	-45	-31	-31	N/A
12/31/2021	3	-47	-30	-30	N/A
9/30/2021	2	-45	-30	-30	N/A
6/30/2021	2	-43	-30	-30	N/A
3/31/2021	2	-39	-29	-29	N/A
12/31/2020	2	-34	-28	-28	N/A
9/30/2020	2	-41	-31	-30	N/A
6/30/2020	2	-48	-33	-33	N/A
3/31/2020	2	-49	-38	-37	N/A
12/31/2019	3	-51	-43	-41	N/A
9/30/2019	3	-46	-38	-37	N/A
6/30/2019	3	-42	-34	-33	N/A
3/31/2019	3	-36	-30	-30	N/A
12/31/2018	3	-30	-26	-26	N/A
9/30/2018	4	-28	-25	-24	N/A
6/30/2018	4	-27	-24	-22	N/A
3/31/2018	4	-26	N/A	-22	N/A
12/31/2017	4	-26	N/A	-21	N/A
9/30/2017	4	-25	N/A	-20	N/A
6/30/2017	4	-24	N/A	-19	N/A
3/31/2017	5	-23	N/A	-19	N/A
12/31/2016	5	-22	N/A	-18	N/A
9/30/2016	5	-21	N/A	-19	N/A
6/30/2016	5	-19	N/A	-20	N/A
3/31/2016	5	-18	N/A	-19	N/A
12/31/2015	4	-17	N/A	-17	N/A
9/30/2015	4	-15	N/A	-15	N/A
6/30/2015	3	-13	N/A	-12	N/A
3/31/2015	3	-11	N/A	-11	N/A
12/31/2014	3	-10	N/A	-9	N/A
9/30/2014	2	-9	N/A	-8	N/A
6/30/2014	2	-8	N/A	-8	N/A
3/31/2014	2	-8	N/A	-7	N/A
12/31/2013	2	-8	N/A	-7	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 5NRA is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: 5NRA is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: 5NRA is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: 5NRA's revenue (7.7% per year) is forecast to grow faster than the German market (5.6% per year).

High Growth Revenue: 5NRA's revenue (7.7% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if 5NRA's Return on Equity is forecast to be high in 3 years time

Nanobiotix Future Growth

Future criteria checks 1/6

Key information

Recent future growth updates

Recent updates

Nanobiotix Announces Progress in Global NBTXR3 Development Collaboration Highlighting Robust Pipeline and Pathway to Long-Term Growth

Nanobiotix S.A. to Report Q1, 2024 Results on May 22, 2024

Nanobiotix Announces US FDA Protocol Acceptance for New Randomized Phase 2 Study Evaluating Nbtxr3 for Patients with Stage Three Lung Cancer

Nanobiotix S.A. to Report Q4, 2023 Results on Apr 24, 2024

Nanobiotix S.A. announced that it has received $24.999999 million in funding from Johnson & Johnson Innovation - JJDC, Inc.

Nanobiotix S.A. to Report Q3, 2023 Results on Nov 13, 2023

Nanobiotix S.A. has completed a Follow-on Equity Offering in the amount of $29.288592 million.

Nanobiotix S.A. has filed a Follow-on Equity Offering in the amount of $30 million.

Nanobiotix S.A. announced that it expects to receive $25 million in funding from Johnson & Johnson Innovation - JJDC, Inc.

Nanobiotix S.A. Announces Updated Preliminary Results from Phase 1 Pancreatic Cancer Trial and New Exploratory Analysis from Completed Phase 1 Head and Neck Cancer Trial at ESMO 2023

Nanobiotix S.A. Announces New Clinical Data from Phase 1 Study Evaluating Radiotherapy-Activated Nbtxr3 for Patients with Pancreatic Ductal Adenocarcinoma

Nanobiotix S.A. to Report First Half, 2023 Results on Sep 26, 2023

NANOBIOTIX Announces Expiration of HSR Waiting Period Regarding the Agreement for Worldwide Co-Development and Commercialization of Potential First-in-Class Radioenhancer NBTXR3

Nanobiotix S.A. Announces First Patient Injected in New Phase 1/2 Study Evaluating Radiotherapy-Activated NBTXR3 Plus Anti-PD-1 for Patients With Advanced Cancers

Nanobiotix S.A., Annual General Meeting, Jun 27, 2023

NANOBIOTIX Announces First Patient Randomized in United States in Global Phase 3 Pivotal Trial Evaluating Radioenhancer NBTXR3 in Head and Neck Cancer

NANOBIOTIX Recommends Phase 2 Dose for NBTXR3 in Pancreatic Cancer

NANOBIOTIX Updates Data from its Phase 1 Immunotherapy Study, Study 1100

NANOBIOTIX Announces the Appointment of Global Medical Experts to Scientific Advisory Board

NANOBIOTIX Establishes Recommends Dose for Planned Registrational Study Evaluating NBTXR3 Plus Anti-PD-1 for Patients With Metastatic Head and Neck Cancer Resistant to Prior Immunotherapy

Nanobiotix S.A. and LianBio Announce First Patient Enrolled in Asia in Phase 3 NANORAY-312 Trial Evaluating NBTXR3 for the Treatment of Head and Neck Cancer

NANOBIOTIX Announces the Reporting of New Data at the 2022 Annual Meeting of the American Society for Clinical Oncology

Nanobiotix S.A. Announces the Reporting of New Data At the 2022 Annual Meeting of the American Society for Clinical Oncology

Nanobiotix S.A. to Report First Half, 2022 Results on Sep 28, 2022

Nanobiotix S.A. Announces New Data from an Open-Label Preclinical Study Evaluating the Combination of First-in-Class Radioenhancer, NBTXR3, with the Triple Blockade of PD-1, LAG-3, and TIGIT

Nanobiotix Announces Publication of New Clinical Case Study Highlighting First Patient Experience of NBTXR3 Treatment for Pancreatic Cancer

Nanobiotix S.A. Announces Publication of New Preclinical Immunotherapy Data Showcasing the Combination Potential of NBTXR3 With anti-PD-1 and anti-CTLA-4

Nanobiotix S.A. Announces First Patient Enrolled in NANORAY-312 Global Phase III Registrational Study of NBTXR3 in Head and Neck Cancer

Nanobiotix S.A. Announces Red Journal Publication of Preclinical Data Showing Radioenhancer NBTXR3 May 'Reprogram' the Tumor Microenvironment to Overcome Anti-PD-1 Resistance and Evoke Abscopal Effect

NANOBIOTIX Announces Initiation of New Clinical Study Evaluating NBTXR3 in Lung Cancer

NANOBIOTIX Reports New Data for Potential First-in-Class Radioenhancer NBTXR3 in Combination With Anti-PD-1 Showing Local or Distant Tumor Regression in 76.9% of Evaluable Patients Regardless of Prior Anti-PD-1 Exposure

Nanobiotix Announces Updated Results From Priority Pathways in Head and Neck Cancer and Immunotherapy for Potential First-in-class Radioenhancer NBTXR3 at 2021 Annual Meeting of the American Society for Clinical Oncology

Nanobiotix S.A. Announces New Data from its Oncology Pipeline to Be Present at the 2021 American Society of Clinical Oncology Annual Meeting

NANOBIOTIX and PharmaEngine, Inc. Mutually Agree to Conclude Collaboration

NANOBIOTIX Announces Positive New Preclinical Data Investigating First-In-Class Radioenhancer NBTXR3

Nanobiotix S.A. to Report Q2, 2021 Results on Sep 03, 2021

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies